Addison Advisors LLC Sells 12,497 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Addison Advisors LLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 85.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,111 shares of the company’s stock after selling 12,497 shares during the quarter. Addison Advisors LLC’s holdings in Takeda Pharmaceutical were worth $28,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Gold Investment Management Ltd. raised its position in shares of Takeda Pharmaceutical by 2.0% in the 3rd quarter. Gold Investment Management Ltd. now owns 73,204 shares of the company’s stock valued at $1,049,000 after acquiring an additional 1,428 shares during the period. Smithfield Trust Co raised its position in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after acquiring an additional 1,490 shares during the period. Kovitz Investment Group Partners LLC raised its position in shares of Takeda Pharmaceutical by 7.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock valued at $362,000 after acquiring an additional 1,670 shares during the period. Aaron Wealth Advisors LLC raised its position in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock valued at $331,000 after acquiring an additional 1,670 shares during the period. Finally, Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at approximately $26,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $14.36 on Wednesday. The company has a market capitalization of $45.68 billion, a price-to-earnings ratio of 35.89, a P/E/G ratio of 0.24 and a beta of 0.51. The firm’s 50 day simple moving average is $13.33 and its 200 day simple moving average is $13.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.